Saturday, 21 November 2020
Pfizer moved to seek emergency authorisation of its Covid-19 vaccine from the US drug regulator, after trials proved over 95 per cent efficacy in preventing infections. The move marks a milestone in months of frantic global hunt for a medicine that could check the pandemic. Once the company files for approval, it is upto the regulator to decide whether the vaccine works safely and is fit for public use. It's also unclear how much time the agency will take to analyse the vaccine data.